{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:00Z","timestamp":1786985220456,"version":"build-2736575974"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004536","name":"Southwest Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004536","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109707","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:12:10Z","timestamp":1772151130000},"page":"109707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting ATR in Cancer therapy: A drug discovery perspective"],"prefix":"10.1016","volume":"174","author":[{"given":"Yue","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2026.109707_bb0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-042320-025136","article-title":"A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade","volume":"73","author":"Ngoi","year":"2022","journal-title":"Annu Rev Med"},{"issue":"27","key":"10.1016\/j.bioorg.2026.109707_bb0015","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1073\/pnas.1903418116","article-title":"An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication","volume":"116","author":"Moiseeva","year":"2019","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0020","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response","volume":"66","author":"Blackford","year":"2017","journal-title":"Molecular cell"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bioorg.2026.109707_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110740","article-title":"Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells","volume":"385","author":"Zhao","year":"2023","journal-title":"Chem Biol Interact"},{"issue":"39","key":"10.1016\/j.bioorg.2026.109707_bb0035","doi-asserted-by":"crossref","first-page":"eado4618","DOI":"10.1126\/sciadv.ado4618","article-title":"ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer","volume":"10","author":"Taniguchi","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.bioorg.2026.109707_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101743","article-title":"The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin","volume":"36","author":"Su","year":"2023","journal-title":"Translational Oncology"},{"issue":"17","key":"10.1016\/j.bioorg.2026.109707_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202318568","article-title":"Discovery of Selective and Potent ATR Degrader for Exploration its Kinase-Independent Functions in Acute Myeloid Leukemia Cells","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0050","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage\u2013Inducing or Repair\u2013Compromising Therapies in Preclinical Cancer Models","volume":"19","author":"Wengner","year":"2020","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cac2.12412","article-title":"Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun (Lond)"},{"issue":"17","key":"10.1016\/j.bioorg.2026.109707_bb0065","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0070","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1038\/s41467-024-51236-6","article-title":"Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy","volume":"15","author":"Patin","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0075","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.bioorg.2026.109707_bb0080","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1158\/1078-0432.CCR-23-1439","article-title":"SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression","volume":"29","author":"Geng","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109707_bb0085","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNA repair"},{"issue":"5233","key":"10.1016\/j.bioorg.2026.109707_bb0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.270.5233.50","article-title":"PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints","volume":"270","author":"Keith","year":"1995","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bioorg.2026.109707_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.sbi.2018.03.010","article-title":"Architecture and activation of phosphatidylinositol 3-kinase related kinases","volume":"49","author":"Imseng","year":"2018","journal-title":"Current opinion in structural biology"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nature reviews. Molecular cell biology"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0968-0004(00)01563-2","article-title":"FAT: a novel domain in PIK-related kinases","volume":"25","author":"Bosotti","year":"2000","journal-title":"Trends in biochemical sciences"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0110","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.yexcr.2007.02.015","article-title":"Function of the ATR N-terminal domain revealed by an ATM\/ATR chimera","volume":"313","author":"Chen","year":"2007","journal-title":"Experimental cell research"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109707_bb0115","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.scib.2025.05.009","article-title":"Molecular architecture and inhibition mechanism of human ATR-ATRIP","volume":"70","author":"Wang","year":"2025","journal-title":"Sci Bull (Beijing)"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"40","author":"Fokas","year":"2014","journal-title":"Cancer treatment reviews"},{"issue":"5547","key":"10.1016\/j.bioorg.2026.109707_bb0125","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science (New York, N.Y.)"},{"issue":"36","key":"10.1016\/j.bioorg.2026.109707_bb0130","doi-asserted-by":"crossref","first-page":"31390","DOI":"10.1074\/jbc.M504961200","article-title":"ATRIP oligomerization is required for ATR-dependent checkpoint signaling","volume":"280","author":"Ball","year":"2005","journal-title":"The Journal of biological chemistry"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell research"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/emboj\/17.1.159","article-title":"Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints","volume":"17","author":"Cliby","year":"1998","journal-title":"The EMBO journal"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molcel.2011.06.019","article-title":"ATR autophosphorylation as a molecular switch for checkpoint activation","volume":"43","author":"Liu","year":"2011","journal-title":"Molecular cell"},{"issue":"33","key":"10.1016\/j.bioorg.2026.109707_bb0150","doi-asserted-by":"crossref","first-page":"28707","DOI":"10.1074\/jbc.M111.248914","article-title":"Thr-1989 phosphorylation is a marker of active ataxia telangiectasia-mutated and Rad3-related (ATR) kinase","volume":"286","author":"Nam","year":"2011","journal-title":"The Journal of biological chemistry"},{"key":"10.1016\/j.bioorg.2026.109707_bb0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annual review of biochemistry"},{"issue":"Suppl. 3","key":"10.1016\/j.bioorg.2026.109707_bb0160","first-page":"633","article-title":"Mechanisms of spontaneous human cancers","volume":"104 Suppl 3","author":"Venitt","year":"1996","journal-title":"Environmental health perspectives"},{"issue":"7267","key":"10.1016\/j.bioorg.2026.109707_bb0165","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109707_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112768","article-title":"The crosstalk between DNA-damage responses and innate immunity","volume":"140","author":"He","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/cr.2007.109","article-title":"The DNA damage response pathways: at the crossroad of protein modifications","volume":"18","author":"Huen","year":"2008","journal-title":"Cell research"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability--an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nature reviews. Molecular cell biology"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","article-title":"Cancer risks among BRCA1 and BRCA2 mutation carriers","volume":"96","author":"Levy-Lahad","year":"2007","journal-title":"British journal of cancer"},{"issue":"7035","key":"10.1016\/j.bioorg.2026.109707_bb0190","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"issue":"5868","key":"10.1016\/j.bioorg.2026.109707_bb0195","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0200","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1124\/mol.105.012716","article-title":"Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival","volume":"68","author":"Karnitz","year":"2005","journal-title":"Molecular pharmacology"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response: convergence of drugs and pathways","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer biology & therapy"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 Axis in Cancer Therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109707_bb0215","article-title":"Targeting the DNA damage response in cancer","volume":"5","author":"Federica","year":"2024","journal-title":"MedComm"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell death & disease"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"British journal of cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0230","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0235","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BJ20102162","article-title":"ATR signalling: more than meeting at the fork","volume":"436","author":"Nam","year":"2011","journal-title":"The Biochemical journal"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109707_bb0240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harbor perspectives in biology"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0245","doi-asserted-by":"crossref","first-page":"13827","DOI":"10.1073\/pnas.2336100100","article-title":"Replication protein A-mediated recruitment and activation of Rad17 complexes","volume":"100","author":"Zou","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0250","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.1547007","article-title":"The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1","volume":"21","author":"Delacroix","year":"2007","journal-title":"Genes & development"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109707_bb0255","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes & development"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0260","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2005.12.041","article-title":"TopBP1 activates the ATR-ATRIP complex","volume":"124","author":"Kumagai","year":"2006","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109707_bb0265","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nature reviews. Cancer"},{"issue":"21","key":"10.1016\/j.bioorg.2026.109707_bb0270","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular Pathways: Targeting ATR in Cancer Therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7011","key":"10.1016\/j.bioorg.2026.109707_bb0275","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nature02964","article-title":"DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1","volume":"431","author":"Ira","year":"2004","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0280","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1038\/sj.emboj.7600469","article-title":"The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle","volume":"23","author":"Aylon","year":"2004","journal-title":"The EMBO journal"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0285","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10409238.2016.1172552","article-title":"Mechanism and regulation of DNA end resection in eukaryotes","volume":"51","author":"Symington","year":"2016","journal-title":"Critical reviews in biochemistry and molecular biology"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0290","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1074\/jbc.M710245200","article-title":"Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair","volume":"283","author":"Chen","year":"2008","journal-title":"The Journal of biological chemistry"},{"issue":"20","key":"10.1016\/j.bioorg.2026.109707_bb0295","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1101\/gad.503108","article-title":"DNA helicases Sgs1 and BLM promote DNA double-strand break resection","volume":"22","author":"Gravel","year":"2008","journal-title":"Genes & development"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011405","article-title":"A Rfa1-MN-based system reveals new factors involved in the rescue of broken replication forks","volume":"21","author":"Amiama-Roig","year":"2025","journal-title":"PLoS genetics"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109707_bb0305","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1093\/nar\/gky625","article-title":"ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells","volume":"46","author":"Kim","year":"2018","journal-title":"Nucleic Acids Research"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0310","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of Homologous Recombination and the Checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Molecular cell"},{"issue":"7213","key":"10.1016\/j.bioorg.2026.109707_bb0315","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nature07215","article-title":"CDK targets Sae2 to control DNA-end resection and homologous recombination","volume":"455","author":"Huertas","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0320","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2009.01.024","article-title":"Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks","volume":"33","author":"Shiotani","year":"2009","journal-title":"Molecular cell"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0325","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0330","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nature reviews. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112721","article-title":"Phosphorylation by ATR triggers FANCD2 chromatin loading and activates the Fanconi anemia pathway","volume":"42","author":"Kupculak","year":"2023","journal-title":"Cell reports"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109707_bb0340","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.celrep.2018.08.019","article-title":"ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links","volume":"24","author":"Mutreja","year":"2018","journal-title":"Cell reports"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0345","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/10409238.2010.502166","article-title":"The Fanconi anemia pathway and ICL repair: implications for cancer therapy","volume":"45","author":"Wang","year":"2010","journal-title":"Critical reviews in biochemistry and molecular biology"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0350","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012724","article-title":"DNA damage response: three levels of DNA repair regulation","volume":"5","author":"Sirbu","year":"2013","journal-title":"Cold Spring Harbor perspectives in biology"},{"issue":"5828","key":"10.1016\/j.bioorg.2026.109707_bb0355","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science (New York, N.Y.)"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109707_bb0360","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nsmb.1504","article-title":"FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway","volume":"15","author":"Ishiai","year":"2008","journal-title":"Nature structural & molecular biology"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109707_bb0365","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2008-05-154294","article-title":"ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function","volume":"113","author":"Collins","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bioorg.2026.109707_bb0370","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1038\/sj.onc.1211034","article-title":"FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3","volume":"27","author":"Wilson","year":"2008","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109707_bb0375","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1101\/gad.1196104","article-title":"ATR couples FANCD2 monoubiquitination to the DNA-damage response","volume":"18","author":"Andreassen","year":"2004","journal-title":"Genes & development"},{"issue":"38","key":"10.1016\/j.bioorg.2026.109707_bb0380","doi-asserted-by":"crossref","first-page":"25560","DOI":"10.1074\/jbc.M109.007690","article-title":"The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR\/ATM pathways","volume":"284","author":"Sobeck","year":"2009","journal-title":"The Journal of biological chemistry"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062182","article-title":"XPA: DNA Repair Protein of Significant Clinical Importance","volume":"21","author":"Borsz\u00e9kov\u00e1 Pulzov\u00e1","year":"2020","journal-title":"International journal of molecular sciences"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0390","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.onc.1209828","article-title":"ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation","volume":"26","author":"Wu","year":"2007","journal-title":"Oncogene"},{"issue":"36","key":"10.1016\/j.bioorg.2026.109707_bb0395","doi-asserted-by":"crossref","first-page":"24213","DOI":"10.1074\/jbc.M109.000745","article-title":"Checkpoint kinase ATR promotes nucleotide excision repair of UV-induced DNA damage via physical interaction with xeroderma pigmentosum group A","volume":"284","author":"Shell","year":"2009","journal-title":"The Journal of biological chemistry"},{"issue":"5293","key":"10.1016\/j.bioorg.2026.109707_bb0400","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.274.5293.1664","article-title":"Cell cycle checkpoints: preventing an identity crisis","volume":"274","author":"Elledge","year":"1996","journal-title":"Science (New York, N.Y.)"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109707_bb0405","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0410","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"S\u00f8rensen","year":"2003","journal-title":"Cancer cell"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0415","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"The Journal of biological chemistry"},{"issue":"6962","key":"10.1016\/j.bioorg.2026.109707_bb0420","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature02082","article-title":"Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage","volume":"426","author":"Busino","year":"2003","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0425","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1101\/gad.1157503","article-title":"SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase","volume":"17","author":"Jin","year":"2003","journal-title":"Genes & development"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109707_bb0430","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/sj.onc.1207394","article-title":"Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis","volume":"23","author":"Busino","year":"2004","journal-title":"Oncogene"},{"issue":"5331","key":"10.1016\/j.bioorg.2026.109707_bb0435","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science (New York, N.Y.)"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0440","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1091\/mbc.12.3.551","article-title":"Positive regulation of Wee1 by Chk1 and 14-3-3 proteins","volume":"12","author":"Lee","year":"2001","journal-title":"Molecular biology of the cell"},{"issue":"14","key":"10.1016\/j.bioorg.2026.109707_bb0445","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes & Development"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1083\/jcb.201008076","article-title":"ATR-mediated phosphorylation of DNA polymerase \u03b7 is needed for efficient recovery from UV damage","volume":"192","author":"G\u00f6hler","year":"2011","journal-title":"The Journal of Cell Biology"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0455","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrm4002","article-title":"DNA replication origin activation in space and time","volume":"16","author":"Fragkos","year":"2015","journal-title":"Nature reviews. Molecular Cell Biology"},{"issue":"27","key":"10.1016\/j.bioorg.2026.109707_bb0460","doi-asserted-by":"crossref","first-page":"28071","DOI":"10.1074\/jbc.M401574200","article-title":"Control of replication origin density and firing time in Xenopus egg extracts: role of a caffeine-sensitive","volume":"279","author":"Marheineke","year":"2004","journal-title":"ATR-dependent checkpoint, The Journal of biological chemistry"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0465","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.molcel.2014.12.003","article-title":"Interaction of Chk1 with Treslin negatively regulates the initiation of chromosomal DNA replication","volume":"57","author":"Guo","year":"2015","journal-title":"Molecular cell"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109707_bb0470","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1074\/jbc.M611292200","article-title":"Cdc7-Dbf4 and the human S checkpoint response to UVC","volume":"282","author":"Heffernan","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0475","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Molecular Cell"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109707_bb0480","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/nm1006-1133","article-title":"Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging","volume":"12","author":"Blackburn","year":"2006","journal-title":"Nature Medicine"},{"issue":"6684","key":"10.1016\/j.bioorg.2026.109707_bb0485","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.adg3224","article-title":"ATR blocks telomerase from converting DNA breaks into telomeres","volume":"383","author":"Kinzig","year":"2024","journal-title":"Science (New York, N.Y.)"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0490","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s44318-024-00066-9","article-title":"ATR limits Rad18-mediated PCNA monoubiquitination to preserve replication fork and telomerase-independent telomere stability","volume":"43","author":"Chen","year":"2024","journal-title":"The EMBO journal"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0495","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1083\/jcb.200908136","article-title":"ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase","volume":"188","author":"McNees","year":"2010","journal-title":"The Journal of cell biology"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0500","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm3591","article-title":"Molecular regulation of stem cell quiescence","volume":"14","author":"Cheung","year":"2013","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.bioorg.2026.109707_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7371-2_1","article-title":"Molecular Regulation of Cellular Quiescence: A Perspective from Adult Stem Cells and Its Niches","volume":"1686","author":"So","year":"2018","journal-title":"Methods in molecular biology (Clifton, N.J.)"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0510","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.tcb.2019.05.002","article-title":"Quiescence: Good and Bad of Stem Cell Aging","volume":"29","author":"T\u00fcmpel","year":"2019","journal-title":"Trends in cell biology"},{"issue":"18","key":"10.1016\/j.bioorg.2026.109707_bb0515","article-title":"ATR activity controls stem cell quiescence via the cyclin F-SCF complex","volume":"119","author":"Salvi","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109707_bb0520","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1016\/j.celrep.2017.08.099","article-title":"The E3 Ubiquitin Ligase SCF(Cyclin F) Transmits AKT Signaling to the Cell-Cycle Machinery","volume":"20","author":"Choudhury","year":"2017","journal-title":"Cell reports"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0525","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.05.046","article-title":"ATR mediates a checkpoint at the nuclear envelope in response to mechanical stress","volume":"158","author":"Kumar","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0530","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1073\/pnas.0914073107","article-title":"PR65, the HEAT-repeat scaffold of phosphatase PP2A, is an elastic connector that links force and catalysis","volume":"107","author":"Grinthal","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yexcr.2014.09.019","article-title":"Replication stress and cancer: it takes two to tango","volume":"329","author":"Lecona","year":"2014","journal-title":"Experimental cell research"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0540","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"The Journal of clinical investigation"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0545","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nsmb.2189","article-title":"Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors","volume":"18","author":"Murga","year":"2011","journal-title":"Nature structural & molecular biology"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109707_bb0550","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-23-3063","article-title":"Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma","volume":"30","author":"Jess","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030359","article-title":"Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer","volume":"17","author":"Lin","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109707_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108755","article-title":"Collateral lethality: A unique type of synthetic lethality in cancers","volume":"265","author":"Zhao","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bioorg.2026.109707_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106050","article-title":"Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib","volume":"177","author":"Wang","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bioorg.2026.109707_bb0570","article-title":"Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells","volume":"12","author":"Yang","year":"2021","journal-title":"Frontiers in pharmacology"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0575","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nature structural & molecular biology"},{"issue":"23","key":"10.1016\/j.bioorg.2026.109707_bb0580","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner","volume":"70","author":"Gilad","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bioorg.2026.109707_bb0585","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert reviews in molecular medicine"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0590","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nature chemical biology"},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2026.109707_bb0595","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","article-title":"Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway","volume":"385","author":"Kwok","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109707_bb0600","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1073\/pnas.161281798","article-title":"ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation","volume":"98","author":"Nghiem","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109707_bb0605","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ng.441","article-title":"Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53","volume":"41","author":"Ruzankina","year":"2009","journal-title":"Nature genetics"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057098","article-title":"Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells","volume":"8","author":"Sultana","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.bioorg.2026.109707_bb0615","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-0-387-09599-8_8","article-title":"XPF\/ERCC4 and ERCC1: their products and biological roles","volume":"637","author":"McDaniel","year":"2008","journal-title":"Advances in experimental medicine and biology"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109707_bb0620","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.bioorg.2026.109707_bb0625","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0630","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s44320-025-00085-6","article-title":"Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response","volume":"21","author":"Hofer","year":"2025","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.bioorg.2026.109707_bb0635","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0640","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27057-2","article-title":"ATR inhibition enables complete tumour regression in ALK-driven NB mouse models","volume":"12","author":"Szydzik","year":"2021","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0645","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/s41467-025-58183-w","article-title":"Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR","volume":"16","author":"Xu","year":"2025","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0650","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156087","article-title":"ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma","volume":"7","author":"Seidel","year":"2022","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.bioorg.2026.109707_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153790","article-title":"Differential Effects of Combined ATR\/WEE1 Inhibition in Cancer Cells","volume":"13","author":"Rodland","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0660","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjh.19218","article-title":"The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib","volume":"204","author":"Sartori","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0665","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11033-024-09431-7","article-title":"Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response","volume":"51","author":"Mihanfar","year":"2024","journal-title":"Mol Biol Rep"},{"issue":"17","key":"10.1016\/j.bioorg.2026.109707_bb0670","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic acids research"},{"key":"10.1016\/j.bioorg.2026.109707_bb0675","first-page":"4375","article-title":"Inhibition of ATM and ATR Kinase Activities by the Radiosensitizing Agent, Caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0680","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"British journal of cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0685","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"10.1016\/j.bioorg.2026.109707_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127517","article-title":"Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor","volume":"30","author":"Bhakuni","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0695","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543776.2022.2027911","article-title":"Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present","volume":"32","author":"Hu","year":"2022","journal-title":"Expert Opin Ther Pat"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0700","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents","volume":"54","author":"Charrier","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"14","key":"10.1016\/j.bioorg.2026.109707_bb0705","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0710","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"British journal of cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0715","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Matulonis, Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0720","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The Novel ATR Inhibitor Tuvusertib (M1774) Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0725","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discovery"},{"issue":"22","key":"10.1016\/j.bioorg.2026.109707_bb0730","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent","volume":"61","author":"Foote","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0735","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13046-022-02526-8","article-title":"ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells","volume":"41","author":"Gao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.bioorg.2026.109707_bb0740","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK\/15\/010)","volume":"29","author":"Ring","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0745","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0750","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175369","article-title":"Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation","volume":"134","author":"Dillon","year":"2024","journal-title":"The Journal of clinical investigation"},{"issue":"17","key":"10.1016\/j.bioorg.2026.109707_bb0755","first-page":"4700","article-title":"Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent","volume":"27","author":"Kim","year":"2021","journal-title":"Combination with Weekly Paclitaxel in Refractory Cancer, Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0760","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0765","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nature medicine"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0770","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.35059","article-title":"Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0775","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0780","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-24-0154","article-title":"Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy","volume":"30","author":"Ng","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0785","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nature medicine"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109707_bb0790","doi-asserted-by":"crossref","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","article-title":"Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers","volume":"67","author":"Carroll","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0795","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0800","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","article-title":"Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109707_bb0805","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0810","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"British journal of cancer"},{"key":"10.1016\/j.bioorg.2026.109707_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114861","article-title":"348 (PB336): ATRN-119, a Novel Macrocyclic ATR Inhibitor, in Patients with Advanced Solid Malignancies: A Phase 1\/2a Trial (ABOYA-119)","volume":"211","author":"Mahipal","year":"2024","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.bioorg.2026.109707_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109707_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"15","key":"10.1016\/j.bioorg.2026.109707_bb0830","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0835","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1021\/acs.jmedchem.4c02380","article-title":"Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor","volume":"68","author":"Wu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2026.109707_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0845","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1021\/acs.jmedchem.1c01999","article-title":"Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain","volume":"65","author":"Karim","year":"2022","journal-title":"J Med Chem"},{"issue":"29","key":"10.1016\/j.bioorg.2026.109707_bb0850","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501916","article-title":"Novel ATR\/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple-Negative Breast Cancer Models","volume":"12","author":"Gao","year":"2025","journal-title":"Advanced Science"},{"key":"10.1016\/j.bioorg.2026.109707_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117160","article-title":"A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase","volume":"241","author":"Wang","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bioorg.2026.109707_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2026.109707_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116167","article-title":"Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase","volume":"267","author":"Alfayomy","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0870","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0875","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202402472R","article-title":"WFDC3 sensitizes colorectal cancer to chemotherapy by regulating ATM\/ATR kinase signaling pathway","volume":"39","author":"Yang","year":"2025","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167625","article-title":"ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer","volume":"1871","author":"Chun","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.bioorg.2026.109707_bb0885","doi-asserted-by":"crossref","first-page":"1603573","DOI":"10.3389\/fphar.2025.1603573","article-title":"Bibliometric analysis of research trends on the combination of radiotherapy and PARP inhibitors in solid tumors","volume":"16","author":"Chen","year":"2025","journal-title":"Frontiers in pharmacology"},{"key":"10.1016\/j.bioorg.2026.109707_bb0890","doi-asserted-by":"crossref","first-page":"1164395","DOI":"10.3389\/fphar.2023.1164395","article-title":"Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer","volume":"14","author":"Dong","year":"2023","journal-title":"Frontiers in pharmacology"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0895","doi-asserted-by":"crossref","first-page":"198","DOI":"10.7150\/ijbs.17240","article-title":"Reverse the Resistance to PARP Inhibitors","volume":"13","author":"Kim","year":"2017","journal-title":"International journal of biological sciences"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109707_bb0900","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020693","article-title":"Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell Lines","volume":"26","author":"Gralewska","year":"2025","journal-title":"International journal of molecular sciences"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109707_bb0905","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41416-024-02935-w","article-title":"Semi-mechanistic efficacy model for PARP+ATR inhibitors\u2014application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs","volume":"132","author":"Villette","year":"2025","journal-title":"British journal of cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0910","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109707_bb0915","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends in pharmacological sciences"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0920","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0142","article-title":"Therapeutic inhibition of ATR in differentiated thyroid cancer","volume":"30","author":"Lin","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0925","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-23-1908","article-title":"AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian Cancer","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0930","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/0008-5472.CAN-23-4129","article-title":"AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy","volume":"84","author":"Ramanarayanan","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0935","article-title":"ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition","volume":"121","author":"Borenas","year":"2024","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109707_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115733","article-title":"Tang, Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity via the cGAS\/STING pathway","volume":"44","author":"Ng","year":"2025","journal-title":"Cell reports"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0945","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s43018-020-00171-8","article-title":"Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma","volume":"2","author":"Roeschert","year":"2021","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0950","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cpdd.1202","article-title":"Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients","volume":"12","author":"Li","year":"2023","journal-title":"Clinical pharmacology in drug development"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0955","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/13543784.2012.666236","article-title":"Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine","volume":"21","author":"Muggia","year":"2012","journal-title":"Expert opinion on investigational drugs"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0960","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/cns.13930","article-title":"5-Fluorouracil reduces the fibrotic scar via inhibiting matrix metalloproteinase 9 and stabilizing microtubules after spinal cord injury","volume":"28","author":"Xu","year":"2022","journal-title":"CNS neuroscience & therapeutics"},{"key":"10.1016\/j.bioorg.2026.109707_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100718","article-title":"Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies","volume":"53","author":"Perez-Ruiz","year":"2020","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0970","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13048-021-00864-3","article-title":"CXCL2-mediated ATR\/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer","volume":"14","author":"Nie","year":"2021","journal-title":"J Ovarian Res"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109707_bb0975","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-24-0151","article-title":"Ruthenium Drug BOLD-100 Regulates BRAFMT Colorectal Cancer Cell Apoptosis through AhR\/ROS\/ATR Signaling Axis Modulation","volume":"22","author":"Griffin","year":"2024","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109707_bb0980","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109707_bb0985","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cac2.12636","article-title":"Radiotherapy-resistant prostate cancer cells escape immune checkpoint blockade through the senescence-related ataxia telangiectasia and Rad3-related protein","volume":"45","author":"Shao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109707_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27082491","article-title":"Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109707_bb0995","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"issue":"19-20","key":"10.1016\/j.bioorg.2026.109707_bb1000","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1101\/gad.351085.123","article-title":"Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR","volume":"37","author":"Zong","year":"2023","journal-title":"Genes & development"},{"key":"10.1016\/j.bioorg.2026.109707_bb1005","article-title":"Dual blockade of BRD4 and ATR\/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer","volume":"3","author":"Kinose","year":"2023","journal-title":"Res Sq rs"},{"key":"10.1016\/j.bioorg.2026.109707_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117305","article-title":"Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition","volume":"286","author":"Li","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"28","key":"10.1016\/j.bioorg.2026.109707_bb1015","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.2174\/0109298673258987231004092334","article-title":"Nanomedicine: Innovative Strategies and Recent Advances in Targeted Cancer Therapy","volume":"31","author":"Gautam","year":"2024","journal-title":"Curr Med Chem"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:00:22Z","timestamp":1777464022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":203,"alternative-id":["S0045206826002439"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109707","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ATR in Cancer therapy: A drug discovery perspective","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109707"}}